In 125 patients also with advanced NSCLC treated with αPD‐(L)1 inhibitors, baseline serum concentrations of IL‐6 ≥13.1 pg/mL were associated with shorter median overall survival (mOS; 7.4 months vs. not reached at 20 months).27 Here, IL6 is linked to non-small cell lung carcinoma.